GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Additional Paid-In Capital

Resverlogix (TSX:RVX) Additional Paid-In Capital : C$73.08 Mil(As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Additional Paid-In Capital?


Resverlogix's quarterly additional paid-in capital declined from Sep. 2023 (C$73.23 Mil) to Dec. 2023 (C$72.76 Mil) but then increased from Dec. 2023 (C$72.76 Mil) to Mar. 2024 (C$73.08 Mil).

Resverlogix's annual additional paid-in capital increased from Dec. 2021 (C$70.81 Mil) to Dec. 2022 (C$74.69 Mil) but then declined from Dec. 2022 (C$74.69 Mil) to Dec. 2023 (C$72.76 Mil).

Resverlogix Additional Paid-In Capital Historical Data

The historical data trend for Resverlogix's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Additional Paid-In Capital Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.68 67.02 70.81 74.69 72.76

Resverlogix Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 72.37 73.23 72.76 73.08

Resverlogix Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Resverlogix Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Resverlogix's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix (TSX:RVX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Additional Paid-In Capital
Comparable Companies
TSXV:SBM XCNQ:BETR TSX:ATE TSX:AEZS XCNQ:ASEP XCNQ:PREV TSXV:KNE XCNQ:MDMA XCNQ:PHRM XCNQ:BIOV OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
RVXCF:USA RFS:Germany
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Website
https://www.resverlogix.com
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines